Atsushi Toyoshima

Suita, 5650871, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Effect of Carbon-Chain Length in [125I]iodophenyl and [211At]astatophenyl Derivatives on Prostate-Specific Membrane Antigen-Targeted Radioligands.

Effect of Carbon-Chain Length in [125I]iodophenyl and [211At]astatophenyl Derivatives on Prostate-Specific Membrane Antigen-Targeted Radioligands.

Journal: Chemical & pharmaceutical bulletin

Published: September 02, 2026

Scale-up production of [211At]PSMA-5 using automated synthesizer for Investigator-Initiated clinical trial.

Scale-up production of [211At]PSMA-5 using automated synthesizer for Investigator-Initiated clinical trial.

Journal: EJNMMI radiopharmacy and chemistry

Published: November 21, 2025

Deformation and Magicity in Heavy Actinides: First Observation of the Ground-State Rotational Band of ^{252}Fm.

Deformation and Magicity in Heavy Actinides: First Observation of the Ground-State Rotational Band of ^{252}Fm.

Journal: Physical review letters

Published: October 16, 2025

Development of PSMA-Targeted Alpha Therapy Using [211At]PSMA-5.

Development of PSMA-Targeted Alpha Therapy Using [211At]PSMA-5.

Journal: Seminars in nuclear medicine

Published: September 02, 2025

First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial).

First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial).

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: July 11, 2025

Feasibility of targeted alpha therapy for Alzheimer's disease using 211At-labeled agent targeting amyloid-β aggregates.

Feasibility of targeted alpha therapy for Alzheimer's disease using 211At-labeled agent targeting amyloid-β aggregates.

Journal: Annals of nuclear medicine

Published: May 28, 2025

First-in-human SPECT/CT imaging of [211At]PSMA-5: targeted alpha therapy in a patient with refractory prostate cancer.

First-in-human SPECT/CT imaging of [211At]PSMA-5: targeted alpha therapy in a patient with refractory prostate cancer.

Journal: European journal of nuclear medicine and molecular imaging

Published: November 08, 2024

Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211.

Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211.

Journal: International journal of molecular sciences

Published: October 27, 2024

Comparison Length of Linker in Compound for Nuclear Medicine Targeting Fibroblast Activation Protein as Molecular Target.

Comparison Length of Linker in Compound for Nuclear Medicine Targeting Fibroblast Activation Protein as Molecular Target.

Journal: International journal of molecular sciences

Published: October 27, 2024

Evaluation of Targeted Alpha Therapy Using [211At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models.

Evaluation of Targeted Alpha Therapy Using [211At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models.

Journal: International journal of molecular sciences

Published: September 14, 2024

Preclinical Evaluation of Biodistribution and Toxicity of [211At]PSMA-5 in Mice and Primates for the Targeted Alpha Therapy against Prostate Cancer.

Preclinical Evaluation of Biodistribution and Toxicity of [211At]PSMA-5 in Mice and Primates for the Targeted Alpha Therapy against Prostate Cancer.

Journal: International journal of molecular sciences

Published: April 17, 2024

Production of [211At]NaAt solution under GMP compliance for investigator-initiated clinical trial.

Production of [211At]NaAt solution under GMP compliance for investigator-initiated clinical trial.

Journal: EJNMMI radiopharmacy and chemistry

Published: January 26, 2024

Showing 1-12 of 44

Last Updated: 09/26/2026